3 withdrawn, 2 recruiting, 1 completed. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Withdrawn 3, Recruiting 2, Completed 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow Xospata: new trials by email Literature Review of Xospata trials Research Report on Xospata
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia Ziftomenib, Fludarabine, Idarubicin - AML, AML With Mutated NPM1 | Phase 1 | Recruiting | Kura Oncology, Inc. | 171 | 2024-02-22 | 2026-08-20 |
| GM-CLAG in Relapsed/Refractory FLT3-mutated AML Gilteritinib 40 MG Oral Tablet, Cladribine, Cytarabine - Acute Myeloid Leukemia | Phase 1 | Withdrawn | Ayman H Qasrawi | 2023-03-01 | 2023-04-25 | |
| Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate - Recurrent Acute Myeloid Leukemia | Phase 1 | Withdrawn | City of Hope Medical Center | 2022-06-25 | 2022-06-09 | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies ERAS-007, ERAS-601, Gilteritinib - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Erasca, Inc. | 2022-03-15 | 2022-06-15 | |
| Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML Gilteritinib, Vyxeos - Acute Myeloid Leukemia With FLT3/ITD Mutation | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 22 | 2022-02-25 | 2025-12-05 |
| A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. Gilteritinib, Idarubicin, Cytarabine - Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Astellas Pharma Inc | 97 | 2015-02-26 | 2025-09-02 |
Leukemia, Myeloid, Acute (5) · Recurrence (2) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Myeloid (1) · Neoplasms by Histologic Type (1)
Astellas Pharma Inc (1) · Ayman H Qasrawi (1) · City of Hope Medical Center (1) · Erasca, Inc. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Kura Oncology, Inc. (1)
United States (5) · Italy (1) · Japan (1) · South Korea (1) · Spain (1) · Taiwan (1)
Ayman Qasrawi, MD (1) · Guido Marcucci (1) · Les Brail, Ph.D. (1) · Onyee Chan, MD (1)
P30CA033572 (1)